Zafgen, Inc. (ZFGN) Director Acquires $39,000.00 in Stock
Zafgen, Inc. (NASDAQ:ZFGN) Director Frances K. Heller acquired 10,000 shares of Zafgen stock in a transaction dated Friday, October 13th. The stock was bought at an average price of $3.90 per share, for a total transaction of $39,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Zafgen, Inc. (NASDAQ:ZFGN) traded down 8.38% during mid-day trading on Tuesday, reaching $3.61. The company’s stock had a trading volume of 150,144 shares. The stock’s 50 day moving average price is $3.49 and its 200 day moving average price is $3.86. Zafgen, Inc. has a 1-year low of $2.89 and a 1-year high of $5.46. The stock’s market capitalization is $99.21 million.
Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter in the previous year, the firm earned ($0.55) EPS. Analysts expect that Zafgen, Inc. will post ($2.23) EPS for the current fiscal year.
Several analysts have recently issued reports on the company. ValuEngine upgraded Zafgen from a “strong sell” rating to a “sell” rating in a research note on Monday. Zacks Investment Research cut Zafgen from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $6.38.
A number of large investors have recently bought and sold shares of ZFGN. Algert Global LLC purchased a new position in Zafgen in the 2nd quarter valued at about $123,000. Parametric Portfolio Associates LLC boosted its position in Zafgen by 55.8% in the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 10,327 shares during the last quarter. Wells Fargo & Company MN boosted its position in Zafgen by 1,290.3% in the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 40,400 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Zafgen in the 2nd quarter valued at about $259,000. Finally, LMR Partners LLP purchased a new position in Zafgen in the 2nd quarter valued at about $299,000. 48.52% of the stock is owned by institutional investors.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.